BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
Bcl-2 overexpression has been shown to be associated with several malignancies, including B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphomas (NHL), mainly low-grade and follicular in type. It has as yet not been described in hairy cell leukemia (HCL). In 30 patients with CLL and 14 with HCL who were consecutively selected for treatment with purine analogues (Fludarabine in CLL and 2-chloro-deoxy-adenosine in HCL), we evaluated bcl-2 oncoprotein expression in leukemic cells on marrow sections that were taken before treatment and stained immunohistochemically with a monoclonal antibody (Dakopatts 124 clone), by the avidin-biotin-peroxidase method. All samples were found to be bcl-2 positive, with a staining intensity that was moderate to strong in CLL and weak to moderate in HCL. 83% of CLL and 100% of HCL patients were responsive to purine analogues. These findings show that bcl-2 is overexpressed in almost all cases CLL and HCL and that bcl-2 overexpression does not predict a poor response to purine analogues, which are believed to induce apoptosis.
Zaja
F
F
Department of Medical and Morphological Research, Udine University Hospital, P.le S. Maria della Misericordia, Italy.
Di Loreto
C
C
Amoroso
V
V
Salmaso
F
F
Russo
D
D
Silvestri
F
F
Fanin
R
R
Damiani
D
D
Infanti
L
L
Mariuzzi
L
L
Beltrami
C A
CA
Baccarani
M
M
D015762:2-Chloroadenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D003839:Deoxyadenosines / Q000627:therapeutic use*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D008297:Male; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003839:Deoxyadenosines; D019253:Proto-Oncogene Proteins c-bcl-2; D015762:2-Chloroadenosine; D014740:Vidarabine; C055994:2-chloro-3'-deoxyadenosine; C024352:fludarabine